MedTrace Logo

Camostat Mesylate in COVID-19 Outpatients

NCT04353284 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2022-03-24

Study results available
· View outcomes & findings →

Summary

The rationale of the present clinical trial is that an orally available drug given to outpatients that could reduce the viral burden in the upper respiratory tract could forestall complications of SARS-CoV-2 infection and reduce transmission from one infected individual to another.

Conditions

Interventions

DRUG

Camostat Mesilate

Camostat mesilate 200mg taken orally, 4 times daily, for 7 days.

OTHER

Placebo

Placebo taken orally, 4 times daily, for 7 days.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Geoffrey Chupp, M.D. · Director, Yale Center for Asthma and Airways Disease (YCAAD)

  • Joseph Vinetz, M.D. · Professor, Section of Infectious Diseases: Department of Internal Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-09
Primary Completion
2021-03-03
Completion
2021-04-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04353284 on ClinicalTrials.gov